Cargando…

The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)

BACKGROUND: Hyperbaric oxygen (HBO) therapy is an effective adjunct treatment for ischemic disorders such as chronic infection or chronic wounds. It combines hyperoxic effects with the stimulating potential of post-therapeutic reactive hypoxia. As its crucial effects, stimulation of fibroblast growt...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Susanne, Wermker, Kai, Poetschik, Harald, Ziebura, Thomas, Kleinheinz, Johannes
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022549/
https://www.ncbi.nlm.nih.gov/pubmed/21176170
http://dx.doi.org/10.1186/1746-160X-6-29
_version_ 1782196514865545216
author Jung, Susanne
Wermker, Kai
Poetschik, Harald
Ziebura, Thomas
Kleinheinz, Johannes
author_facet Jung, Susanne
Wermker, Kai
Poetschik, Harald
Ziebura, Thomas
Kleinheinz, Johannes
author_sort Jung, Susanne
collection PubMed
description BACKGROUND: Hyperbaric oxygen (HBO) therapy is an effective adjunct treatment for ischemic disorders such as chronic infection or chronic wounds. It combines hyperoxic effects with the stimulating potential of post-therapeutic reactive hypoxia. As its crucial effects, stimulation of fibroblast growth, induction of collagen synthesis and the initiation of angiogenesis are discussed. Angiogenesis is a multistage process resulting in the growth of blood vessels. It includes degradation of extracellular matrix, proliferation and migration of different cell populations and finally formation of new vessel structures. This complex chain of procedures is orchestrated by different cytokines and growth factors. Crucial mediators of angiogenesis are basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF); their in-vivo function is still not fully understood. METHODS: Forty-three patients suffering from sudden sensorineural hearing loss or tinnitus were treated with HBO. The therapy included 10 sessions of 90 minutes each, one session a day. Serological levels of bFGF and VEGF were assessed by enzyme-linked immunosorbent assays performed according to the manufacturer's instructions on day 1, 2, 5 and 10 of HBO therapy and were compared to mean values of the control group, related to the patient's age and sex, and their development observed over the ten days of HBO. RESULTS: There was no sex- or age dependency of bFGF observed in the present study, whereas under HBO our results showed a significant mitigation of the bFGF concentration. In the present data, there was no connection between the VEGF concentration and the patients' ages. Women showed significantly higher levels of VEGF. There was no significant change of VEGF concentration or the VEGF/bFGF ratio during HBO. All scored results varied within the range of standard values as described in the current literature. CONCLUSIONS: A significant effect of HBO on serum concentrations of bFGF and VEGF was not verified in the present study. Additional application of exogenous growth factors in conjunction with HBO was not obviously linked by a coherent cause-and-effect chain as far as wound healing is concerned.
format Text
id pubmed-3022549
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30225492011-01-19 The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) Jung, Susanne Wermker, Kai Poetschik, Harald Ziebura, Thomas Kleinheinz, Johannes Head Face Med Research BACKGROUND: Hyperbaric oxygen (HBO) therapy is an effective adjunct treatment for ischemic disorders such as chronic infection or chronic wounds. It combines hyperoxic effects with the stimulating potential of post-therapeutic reactive hypoxia. As its crucial effects, stimulation of fibroblast growth, induction of collagen synthesis and the initiation of angiogenesis are discussed. Angiogenesis is a multistage process resulting in the growth of blood vessels. It includes degradation of extracellular matrix, proliferation and migration of different cell populations and finally formation of new vessel structures. This complex chain of procedures is orchestrated by different cytokines and growth factors. Crucial mediators of angiogenesis are basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF); their in-vivo function is still not fully understood. METHODS: Forty-three patients suffering from sudden sensorineural hearing loss or tinnitus were treated with HBO. The therapy included 10 sessions of 90 minutes each, one session a day. Serological levels of bFGF and VEGF were assessed by enzyme-linked immunosorbent assays performed according to the manufacturer's instructions on day 1, 2, 5 and 10 of HBO therapy and were compared to mean values of the control group, related to the patient's age and sex, and their development observed over the ten days of HBO. RESULTS: There was no sex- or age dependency of bFGF observed in the present study, whereas under HBO our results showed a significant mitigation of the bFGF concentration. In the present data, there was no connection between the VEGF concentration and the patients' ages. Women showed significantly higher levels of VEGF. There was no significant change of VEGF concentration or the VEGF/bFGF ratio during HBO. All scored results varied within the range of standard values as described in the current literature. CONCLUSIONS: A significant effect of HBO on serum concentrations of bFGF and VEGF was not verified in the present study. Additional application of exogenous growth factors in conjunction with HBO was not obviously linked by a coherent cause-and-effect chain as far as wound healing is concerned. BioMed Central 2010-12-22 /pmc/articles/PMC3022549/ /pubmed/21176170 http://dx.doi.org/10.1186/1746-160X-6-29 Text en Copyright ©2010 Jung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jung, Susanne
Wermker, Kai
Poetschik, Harald
Ziebura, Thomas
Kleinheinz, Johannes
The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)
title The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)
title_full The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)
title_fullStr The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)
title_full_unstemmed The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)
title_short The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)
title_sort impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (vegf) and basic fibroblast growth factor (bfgf)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022549/
https://www.ncbi.nlm.nih.gov/pubmed/21176170
http://dx.doi.org/10.1186/1746-160X-6-29
work_keys_str_mv AT jungsusanne theimpactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT wermkerkai theimpactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT poetschikharald theimpactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT zieburathomas theimpactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT kleinheinzjohannes theimpactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT jungsusanne impactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT wermkerkai impactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT poetschikharald impactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT zieburathomas impactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf
AT kleinheinzjohannes impactofhyperbaricoxygentherapyonserologicalvaluesofvascularendothelialgrowthfactorvegfandbasicfibroblastgrowthfactorbfgf